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1  | INTRODUCTION
Patients	with	 cirrhosis	 frequently	 present	with	 complex	 hemostatic	
 alterations.1	 It	 has	been	proposed	 that	 the	net	 effect	 of	 the	hemo-
static	changes	in	these	patients	is	a	rebalanced,	yet	precarious,	hemo-
static	system.	Indeed,	depending	on	the	nature	of	the	trigger	and	exact	






in cirrhosis.1	 In	contrast,	more	advanced	hemostasis	 tests	 that	mea-
sure	 global	 hemostasis,	 including	 thrombin	 generation	 assay	 (TGA)	







sults	of	patients	with	 cirrhosis	 are	generally	 comparable	 to	 those	of	
healthy individuals. These seminal observations have contributed to 











commercially	 available,	 thromboelastography	 (TEG)	 and	 rotational	











Studies	 so	 far	 have	 been	 limited	 by	 relatively	 small	 cohorts	 or	
	cohorts	of	mixed	etiology.	Therefore,	it	is	yet	unknown	whether	VET	
parameters	 are	 similar	 across	 different	 etiologies	 of	 cirrhosis	 and	
hence	reflect	a	similar	baseline	hemostatic	function	across	the	whole	
patient	 group.	 It	 is	 also	 unknown	 whether	 subdividing	 hemostatic	









2  | PATIENTS & METHODS

























lines	of	 the	1975	Declaration	of	Helsinki	 and	was	approved	by	 the	
medical	ethics	committee	of	VCU	Medical	Center.
2.1 | Definition of complications and final 
outcomes of cirrhosis
Patients	were	 seen	every	6	months	 (for	Child’s	 class	A	patients)	 or	
at	 least	 every	3	months	 (for	Child’s	 class	B/C	patients)	 as	 a	matter	
of	routine	by	one	investigator	(RTS).	Electronic	medical	records	were	
reviewed	on	each	visit,	and	patients	were	specifically	asked	whether	




Bleeding	 complications	 specifically	 included	 spontaneous	 (non-	
procedure-	related)	gastrointestinal	bleeding	from	any	source,	the	need	
for	blood	transfusion	with	evidence	of	blood	loss,	or	other	significant	
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blood	 loss.	Epistaxis	was	not	 included	 in	the	assessment	of	bleeding	
complication	 unless	 it	 required	 intervention.	 Thrombotic	 complica-
tions	specifically	included	spontaneous	(non-	procedure-	related)	deep	
venous	 thrombosis	 of	 the	 arms	 legs	 and/or	 pulmonary	 embolism	or	
new	occlusive	portal	venous	thrombosis	on	ultrasound	during	6-	month	
surveillance	exams	for	hepatocellular	carcinoma.	Final	outcomes	of	cir-
rhosis	 included	 transplant-	free	 survival,	 orthotopic	 liver	 transplanta-
tion	(OLT),	or	death.
2.2 | Thromboelastography
Thromboelastography	 was	 performed	 on	 a	 single	 instrument	
(Thrombelastograph	Haemostasis	Analyzer	5000;	Haemonetics	Corp.,	
Haemoscope	Division,	Niles,	 IL,	USA).	Briefly,	5	mL	of	3.2%	citrated	
whole	 blood	 was	 subjected	 to	 TEG	 within	 2	hour	 of	 blood	 draw.	
Clotting	was	 initiated	 at	 37°C	by	 the	 addition	of	 40	μL	of	 kaolin	 to	









PT/INR,	 platelet	 counts,	 and	 plasma	 levels	 of	 fibrinogen	were	 as-
sayed	 by	 the	 Clinical	 Coagulation	 Laboratory	 at	 VCU.	 The	 PT/
INR	 and	 fibrinogen	 plasma	 concentration	 were	 determined	 using	
the	 automated	 STA-	R	 Evolution	 clot	 detection	 system.	 The	 PT/
INR	 was	 determined	 using	 re-	calcified	 plasma	 and	 recombinant	
human	 tissue	 factor	 and	 synthetic	 thromboplastin	 (Dade	 Innovin-	
Reagent;	Siemens	Healthcare	Diagnostics	Products	GmbH,	Marburg,	




Continuous	 data	 were	 tested	 for	 normality	 and	 expressed	 as	
mean±standard	 deviation	 (SD)	 or	 median	 [range],	 and	 analyzed	 by	
analysis	 of	 variance	 (ANOVA)	 or	 Wilcoxon/Kruskal–Wallis	 Rank	






3.1 | Demographic, laboratory, and clinical 
characteristics of patients with cirrhosis
Patient	demographics,	vital	signs,	and	 laboratory	test	 results	at	 the	





in	 cholestatic	 disease,	 but	 this	was	 not	 significantly	 higher	 than	 in	
other	 etiologies	of	 cirrhosis.	However,	 patients	who	 suffered	 from	
cholestatic	 cirrhosis	 had	 significantly	 higher	 fibrinogen	 levels	 (me-
dian	396	mg	dL−1	compared	 to	191	mg	dL−1	 in	HBV/HCV	cirrhosis,	
for	 example).	 Combined,	 26%	 of	 the	 patients	 developed	 a	 bacte-
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encephalopathy,	 3%	 thrombosis,	 and	 11%	 suffered	 from	 bleeding	
complications.	At	the	end	of	the	study,	71%	of	the	patients	had	been	
hospitalized,	 19%	 underwent	 liver	 transplantation,	 and	 46%	 died.	
The	mean	time	from	performing	TEG	to	bleeding	was	347	days	and	
72	days	to	thrombosis.	 It	was	328	days	to	 liver	transplantation	and	
484	days	 to	 death.	 Patients	 in	 the	 cholestatic	 patient	 group	 were	
up	 to	 10	 time	 less	 likely	 to	 develop	 encephalopathy	 (3%),	 but	 2-	3	
times	more	 likely	 to	undergo	 liver	 transplantation	 (44%)	 compared	
to	 patients	 suffering	 from	 other	 etiologies	 of	 cirrhosis,	 whilst	 the	
distribution	 among	classes	of	disease	 severity	between	 the	groups	
was	similar	(ie,	Child-	Pugh	and	MELD).
3.2 | Normal R- times in cirrhosis 
regardless of the etiology
In	Figure	2A,	it	is	shown	that	the	R-	time,	indicating	the	latency	of	clot	
formation,	 was	 generally	 within	 normal	 range	 when	 patients	 were	
combined,	with	 a	median	 (range)	 of	 4.3	minute	 (1-	9.7)	 (normal	 range	






































































































































































































































3.3 | Normal- to- increased K- times in cirrhosis 
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(0.8-	9.5)	in	HBV/HCV;	1.8	minute	(0.8-	8.9)	in	ETOH;	2.1	minute	(0.9-	
6.3)	 in	NASH;	2.0	minute	 (0.8-	6.2)	 in	other	non-	cholestatic	 cirrhotic	
patients	and	2.1	minute	 (0.9-	15.2)	 in	cirrhotic	patients	with	HCC.	 In	
contrast,	the	median	K-	time	was	1.4	minute	(0.8-	6.2)	in	patients	with	
cholestatic	 cirrhosis,	which	was	 significantly	 lower	 than	each	of	 the	
other	groups,	ETOH	cirrhosis	excepted.	Indeed,	only	10%	of	patients	
in	 the	 cholestatic	 group	 presented	 with	 K-	times	 above	 the	 normal	
range.
3.4 | Normal- to- decreased α- Angles in cirrhosis 











rhotic	 patients	with	HCC.	 In	 patients	with	 cholestatic	 cirrhosis,	 the	
median α-	Angle	 was	 70.3	 degrees	 (37.5-	79),	 which	 is	 significantly	
higher	than	each	of	the	other	groups.
3.5 | Normal- to- decreased MA in non- cholestatic 









54.2	mm	 (35.7-	69.3)	 in	 other	 non-	cholestatic	 cirrhosis	 patients	 and	
50.8	mm	 (24.7-	69.2)	 in	 cirrhotic	 patients	 with	 HCC.	 Whereas	 the	
largest	proportion	of	patients	with	non-	cholestatic	cirrhosis	had	MA	
values	within	or	below	 reference	 range,	43%	of	 the	 cholestatic	pa-
tients	had	values	above	it.	Indeed,	the	median	MA	in	this	group	was	
63.8	mm	 (33.5-	79.7),	which	 is	 significantly	 higher	 than	 each	 of	 the	
other	groups.
3.6 | Normal Ly- 30 in cirrhosis 









3.7 | K- time, α- Angle and MA correlate with 
platelets and fibrinogen in cirrhosis
In	 this	 large	 group	 of	 patients	 with	 cirrhosis,	 K-	time,	 α-	Angle	 and	
MA	 correlated	 with	 platelet	 count	 (r=−.45;	 r=.52;	 r=.74,	 respec-
tively; P<.0001)	as	well	as	with	fibrinogen	levels	(r=−.52;	r=.55,	r=.78,	
	respectively;	P<.0001).	These	correlations	were	consistent	regardless	
of	 the	 etiology,	 as	 further	 demonstrated	 in	 Table	3.	 Platelet	 count,	
	fibrinogen	levels,	as	well	as	INR	also	associated	with	disease	severity	
as	shown	in	Figure	3F–H.
3.8 | TEG parameters at admission do not predict 
thrombosis, bleeding events, and transplantation or 
death in patients with cirrhosis
As	shown	in	Figure	4,	TEG	parameters	at	baseline	did	not	significantly	
differ	 between	 patients	 who	 experienced	 thrombosis	 or	 bleeding	
events	during	 follow-	up	or	between	patients	 that	underwent	 trans-










The	 above	 study	 of	 kaolin-	initiated	 TEG	 shows	 a	 generally	 pre-
served	 function	 of	 the	 hemostatic	 system	 in	 cirrhosis.	 This	 is	 in	
line	 with	 earlier	 studies	 using	 TEG	 in	 patients	 with	 cirrhosis.5,13 












reflective	 of	 the	 cohort	 as	 a	whole.	 Indeed,	 compared	 to	 the	 other	
etiologies,	TEG	values	 in	patients	with	cholestatic	 liver	disease	were	
significantly	 different.	 This	 group	 demonstrated	 hypercoagulable	
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tendencies,	 notably	 increased	 MA	 values	 above	 the	 normal	 upper	
limit,	probably	because	of	higher	fibrinogen	concentrations	and	plate-
let	count	compared	to	the	other	etiologies	in	combination	with	plate-
let	hyperreactivity,	which	 is	 in	 accordance	with	previous	 studies.6,14 
Ultimately,	 however,	 clot	 dissolution	 30	minute	 after	 MA	 was	 well	
within	normal	 limits	 in	all	groups.	 In	addition,	despite	some	patients	
having	abnormal	TEG	measurements	on	admission,	this	had	no	impli-
cation	 for	 their	 clinical	 outcome:	TEG	parameters	 between	patients	
that	did	or	did	not	experience	bleeding,	thrombosis,	death	and/or	liver	






















While	 the	 results	 of	 this	 study	 confirm	 relatively	 preserved	









ing	 at	 patients	with	 cirrhosis	 undergoing	 invasive	 procedures,	 com-
pared	standard	hemostasis	screening	tests	(platelet	count	and	PT)	with	







here	 can	 easily	 be	 explained	 by	 the	 current	 notion	 that	 bleeding	 in	
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Kaolin-	modified	TEG	is	 inherently	 limited	by	 its	 initiation	of	the	 in-
trinsic	clotting	cascade	which	does	not	reflect	physiological	(tissue-	factor	
driven	[TF])	clotting	dynamics.	However,	even	in	TF-	triggered	TEG,	the	







these are relatively resistant to lysis.25	The	proposed	underlying	mech-
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cases	of	thrombosis	in	cholestatic	disease	group,	which	clearly	stood	



















detection	 in	 hospitalized	 patients	with	 cirrhosis.	 Prospectively,	 TEG	
could	even	guide	thromboprophylaxis	by	measuring	individual	and	po-
tentially	supra-	/sub-	clinical	response	to	therapy.
In	 conclusion,	 a	 single	 kaolin-	activated	TEG	measurement	 does	
not	predict	future	bleeding	or	thrombosis	in	stable	patients	with	cir-
rhosis.	Future	studies	designed	to	determine	 if	 the	TEG	 is	sensitive	
enough	 to	 detect	 hemostatic	 changes	 in	 cirrhosis	 should	 include	
either	 serial	 TEG	measurements	 from	 baseline	 up	 to	 the	 bleeding/
thrombotic	event	(to	better	evaluate	the	dynamic	nature	of	the	hemo-
static	abnormalities	in	patients	with	cirrhosis),	and/or	a	TEG	measure-
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